AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

RecruitingNAAges 18 Years - anyFemaleScreenCell
💬

In plain words

What the trial is, and whether it could suit you

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening
💊

What it tests

  • The DM/DIV ScreenCell is the experimental product studied during this research
📍

Where

1 site
CMC Ambroise Paré Hartmann
Neuilly-sur-Seine, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy